Device Trial Radar · NCT02979587
The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
86
Actual
Start
Jan 2017
Primary completion
Jul 17, 2020
Study completion Feb 2031
Sponsor
- Lead sponsor
- Medtronic Heart ValvesPublic (MDT)
- Sponsor type
- Industry
- First posted
- Dec 1, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have transitioned into a post-approval study to confirm the long-term functionality of transcatheter implantation of the Medtronic Harmony TPV.
Conditions
- Congenital Heart Disease
- Tetrology of Fallot
- RVOT Anomaly
- Pulmonary Regurgitation
Interventions
Harmony TPV SystemDevice
The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame. The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience). The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom From Procedure- or Device-related Mortality at 30 Days.Time frame: 30 days
- Number of Participants With Acceptable Hemodynamic Function Composite at 6 MonthsTime frame: 6 months
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Ronald Regan UCLA Medical Center
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
Yale University
New Haven, Connecticut
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.